• Explore /
  • Poster
  • / Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.

Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.

Abstract Poster

Authors

Sakti Chakrabarti

Sakti Chakrabarti

Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

Sakti Chakrabarti , J. Eva Selfridge , Marie Parish , David L Bajor , Antony Ruggeri , Sameer Tolay , Madison Conces , Melissa Amy Lumish , AMR MOHAMED , Amit Mahipal , Aditya V. Shreenivas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 736)

DOI

10.1200/JCO.2024.42.3_suppl.736

Abstract #

736

Poster Bd #

L11

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).

First Author: Aaron Scott Mansfield

First Author: Charlee Nardin

First Author: Joseph Vento

First Author: Sakti Chakrabarti